Universal reference book for medicines
Product name: ADGELON ® (ADGELON)

Active substance: nonappropriate

Type: A drug stimulating the process of cartilage tissue regeneration

Manufacturer: ЭНДО-ФАРМ-А ПП (Russia)
Composition, form of production and packaging
Solution for intraarticular administration
in the form of a transparent, colorless liquid, odorless.

1 ml

Adegelone (0.01% glycoprotein solution in water for injection) 10 -9 ml

Excipients: sodium chloride, calcium chloride, water d / and.

2 ml - ampoules (10) - packings of cellular contour (1) - packs cardboard.

5 ml - bottles (10) - packs cardboard.

10 ml - bottles (10) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2015.

PHARMACHOLOGIC EFFECT

The drug that stimulates the process of regeneration of cartilaginous tissue.
The active substance of the preparation is a glycoprotein, isolated from blood serum of cattle.
The drug inhibits the process of degeneration and stimulates the regeneration of cartilage tissue in case of damage.
Stimulates the growth of fibroblast cultures, proliferative activity of lymphocytes, prevents the development of the inflammatory process, has antioxidant properties, prevents damage to the membrane structures of cells under various pathological conditions. Strengthens the adhesive interactions of cells of mesenchymal origin. If the articular cartilage is damaged, it stimulates the accumulation of chondroblasts, their differentiation into chondrocytes, the filling of the damaged area with chondrocytes, the restoration of the joint surface and joint mobility. Strengthens the production of chondrocytes of the cartilaginous matrix, collagen type II, proteoglycans. Promotes the ordering of the matrix structure.
Eliminates or reduces pain syndrome.

PHARMACOKINETICS

Data on the pharmacokinetics of the drug Adgelon ® are not provided.

INDICATIONS

osteoarthritis of large joints.

DOSING MODE

Enter intra-articularly 2 ml 2 times a week or every other day in the aseptic conditions of the treatment room.
Simultaneously, you can enter into several joints.
Course - 5-10 injections, depending on the severity of the disease.
The interval between courses is not less than 4 weeks.
SIDE EFFECT

Systemic reactions: allergic reactions.

Local reactions: pain, redness, swelling of tissues in the area of ​​administration of the drug.

CONTRAINDICATIONS

- infectious lesions of the skin and tissues in the joint region;

- pronounced synovitis;

- Children's age (no data on effectiveness and safety);

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

Data on the use of the drug Adgeelon ® during pregnancy and lactation (breastfeeding) is currently not available.

APPLICATION FOR CHILDREN

Contraindication: child age (no data on efficacy and safety).

SPECIAL INSTRUCTIONS

When complex therapy is recommended to observe the time interval (several hours) between injections of Adegelon and other drugs.

When expressed synovitis, the administration of the drug is recommended after arresting the process or puncturing the joint and removing the exudate.

Before handling, the solution must be heated to room temperature.
After the introduction of the patient is recommended to maintain a sparing regimen and avoid excessive stress on the joint for 1-2 days.
When unwanted reactions occur at the injection site, a cold compress (ice) is applied to the joint for 10-15 minutes.

OVERDOSE

Currently there have been no reports of overdose of Adgelon ® .

DRUG INTERACTION

Drug interaction of the drug Adgeelon ® with antibiotics, GCS, NSAIDs is not revealed.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, protected from light, out of reach of children at a temperature of 4 ° to 20 ° C.
Shelf life - 3 years.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!